genedrive plc

("genedrive", the "Group" or the "Company")

Publication of Circular and Notice of General Meeting

London, UK - 24 April 2023: genedrive plc (LSE: GDR), the point of care molecular diagnostics company, announces that further to the announcement on 31 March 2023 confirming that it had agreed terms on an Equity Prepayment Facility for up to £5 million, a Circular will shortly be published on the Company's website, www.genedriveplc.com, and will be posted to Shareholders later today.

The Circular contains the notice convening the General Meeting to be held at 11.00 a.m. on 11 May 2023 at which resolutions will be proposed to authorise the allotment of new ordinary shares and the disapplication of pre-emption rights.

For further information, please contact:

About genedrive plc (http://www.genedriveplc.com)

 genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

The Genedrive® MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects, is the world's first commercial point-of-care genetic test for emergency care. It helps to avoid irreversible lifelong hearing loss in specific infants exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant that can cause lifelong deafness, allowing for alternative antibiotics to be prescribed. Product information can be found at https://www.genedrive.com/assays/rnr1-product.php